Modern strategies for early diagnosis of cardiotoxicity caused by chemotherapy

Lykova A.A.; Khidirova L.D.

doi:https://doi.org/10.17116/profmed202528111113

OBJECTIVE

To evaluate current cardiovascular imaging and monitoring techniques used for early detection of cardiotoxicity.

MATERIALS AND METHODS

The review methodology involved searching and analyzing scientific data from Russian and international publications, selected by keywords and topics, in the PubMed, Scopus, Web of Science, and eLibrary databases for the period from 2015 to 2025, considering relevance and scientific significance criteria.

RESULTS

Two-dimensional and three-dimensional echocardiography capabilities are presented, including evaluation of global longitudinal myocardial strain as a sensitive marker of early systolic dysfunction. The diagnostic advantages of magnetic resonance imaging (MRI) of the heart, which provides an accurate quantitative assessment of myocardial morphology and tissue characteristics, are highlighted. Radioisotope methods, including scintigraphy and positron emission tomography, are considered to assess perfusion, metabolism, and cellular damage. The advantages of using myocardial damage biomarkers to detect cardiotoxicity in the early stages were analyzed.

CONCLUSION

The integration of these methods into clinical practice contributes to personalized monitoring, increased safety of anticancer treatment, and a reduced risk of cardiovascular complications.

Keywords:

cardiotoxicity

myocardial damage

imaging

early diagnosis

echocardiography

magnetic resonance imaging of the heart

cardiac MRI

positron emission tomography

PET

global longitudinal myocardial deformation

highly sensitive troponin I and T

N-terminal Brain Natriuretic ProPeptide

cytokines

microRNA

Authors:

Lykova A.A.

Novosibirsk Clinical Cardiology Dispensary

ORCID: 0009-0008-2118-2639

Khidirova L.D.

Novosibirsk State Medical University;
Novosibirsk Clinical Cardiology Dispensary

SPIN RSCI: 7932-6544
Scopus AuthorID: 57195757496
ORCID: 0000-0002-1250-8798

Received:

14.07.2025

Accepted:

08.08.2025

Close metadata

References:

Rukovodstvo po kardioonkologii. Pod red. Kaprina AD, Potievskoj VI. M.: GEOS. 2024. (In Russ.).
Lefrak EA, Piecha J, Rosenheim S, et al. Clinicopathological analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302-314. https://doi.org/10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2
Bergamini S, Dolci G, Rossi A, et al. Left atrial volume in HER2-positive breast cancer patients: another step toward predicting trastuzumab-related cardiotoxicity. Clinical Cardiology. 2018;41(3):349-353. https://doi.org/10.1002/clc.22872
Cardinale DM, Zaninotto M, Cipolla CM, et al. Cardiotoxic effects and myocardial injury: searching for a more precise definition of drug-induced cardiotoxicity. Clinical Chemistry and Laboratory Medicine. 2020;59(1):51-57. https://doi.org/10.1515/cclm-2020-0566
Fashafsha ZZ, Chomakhidze PSh, Mesitskaya DF, et al. Early echocardiographic alterations in cancer patients during chemotherapy. Rossijskij kardiologicheskij zhurnal. 2022;27(11):5093. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5093
Avalyan AA, Saidova MA, Oshchepkova EV, et al. Speckle-tracking echocardiography in 3D mode in assessing myocardial deformation and detecting subclinical cardiotoxicity during chemotherapy in breast cancer patients with arterial hypertension. Sistemnye gipertenzii. 2020;17(3):42-47. (In Russ.). https://doi.org/10.26442/2075082X.2020.3.200334
Saidova MA, Avalyan AA, Oshchepkova EV, et al. Comparative capabilities of speckle-tracking echocardiography in 2D and 3D modes in detecting subclinical cardiotoxicity in breast cancer patients. Terapevticheskij arhiv. 2020; 92(12):142-147. (In Russ.). https://doi.org/10.26442/00403660.2020.12.200431
Hong YJ, Kim GM, Han K, et al. Cardiotoxicity from the point of view of magnetic resonance imaging in patients with breast malignancies (CARE BEST): recent research. BMC Cardiovascular Disorders. 2020;20:264. https://doi.org/10.1186/s12872-020-01497-y
Onk G, Dresden-Mysly K, Dhir V, et al. Visualization of myocardial deformity by cardiac MRI to detect subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. International journal of cardiology. 2018;261:228-233. https://doi.org/10.1016/j.ijcard.2018.03.041
Vitsenia MV, Ageev FT, Gilyarov MYu, et al. Practical recommendations for the correction of cardiovascular toxicity of antitumor therapy. Zlokachestvenny`e opuxoli: Prakticheskie rekomendacii RUSSCO. 2021;11(3-2):78-98. (In Russ.).
Ansheles AA, Sergienko IV, Prus YA, et al. Nuclear imaging of chemotherapy-induced cardiotoxicity. Kardiovaskuljarnaja terapija i profilaktika. 2021; 20(2):2537. (In Russ.). https://doi.org/10.15829/1728-8800-2021-2537
Safee ZM, Baark F, Waters ECT, et al. Detection of anthracycline-induced cardiotoxicity using perfusion-corrected (99m)Tc sestamibi SPECT. Scientific Reports. 2019;9(1):216. https://doi.org/10.1038/s41598-018-36721-5
Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting chemotherapy response in lung cancer patients: systematic review and meta-analysis. Journal of Nuclear Medicine. 2009;50(3):376-381. https://doi.org/10.2967/jnumed.108.055988
Prus Y, Sergienko I, Ansheles A, et al. Effect of chemotherapy on myocardial perfusion and function. Atherosclerosis. 2019;287:e253. https://doi.org/10.1016/j.atherosclerosis.2019.06.779
Miele E, Spinelli GP, Tomao F, et al. Positron emission tomography (PET) radiotracers in oncology — utility of 18F-FDG PET in management of non-small-cell lung cancer. Journal of Experimental and Clinical Cancer Research. 2008;27:52. https://doi.org/10.1186/1756-9966-27-52
Nensa F, Kloth J, Tezgah E, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. Journal of Nuclear Cardiology. 2018;25(3):785-794. https://doi.org/10.1007/s12350-016-0616-y
Radionuklidnaya diagnostika dlya prakticheskix vrachej. Pod red. Lishmanova YuB, Chernova VI. Tomsk: STT. 2004. (In Russ.).
Abidov A, Germano G, Hachamovitch R, et al. Gated SPECT assessment of regional and global left ventricular function: an update. Journal of Nuclear Cardiology. 2013;20(6):1118-1143;quiz 1146. https://doi.org/10.1007/s12350-013-9792-1
Potievskaya VI, Akhobekov AA, Kononova EV. Relationship between cardiac arrhythmias and anticancer therapy. Kardiovaskuljarnaja terapija i profilaktika. 2020;19(5):2417. (In Russ.). https://doi.org/10.15829/1728-8800-2020-2417
Matskeplishvili ST, Potievskaya VI, Popovkina OE, et al. Cardiovascular complications of oncology treatment (cardiooncology): prevention, diagnosis, treatment — consensus of experts. Technologies of Living Systems. 2018; 15(6):3-35.
Vasyuk YuA, Shupenina EY, Nosova AG, et al. Vasotoxic Effects of Anticancer Therapy: a Review of Current Data. Racional’naja farmakoterapija v kardiologii. 2023;19(2):203-208. (In Russ.). https://doi.org/10.20996/1819-6446-2023-03-03
Emelina EI, Gendlin GE, Nikitin IG, et al. Rhythm and Conduction Disorders in Patients Receiving Ibrutinib. Klinicheskaya onkogematologiya. 2019; 12(2):220-230. (In Russ.). https://doi.org/10.21320/2500-2139-2019-12-2-220-230
Brahmer JR, Lacchetti C, Schneider J, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline. Journal of Clinical Oncology. 2018;36(17):1714-1768. https://doi.org/10.1200/JCO.2017.77.6385
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from SITC Toxicity Management Working Group. Journal for Immunotherapy of Cancer. 2017;5(1):95. https://doi.org/10.1186/s40425-017-0300-z
Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for Immunotherapy of Cancer. 2016;4:50. https://doi.org/10.1186/s40425-016-0152-y
Behling J, Kaes J, Munzel T, et al. New-onset third-degree atrioventricular block due to autoimmune-induced myositis under anti-PD-1 (nivolumab) treatment for metastatic melanoma. Melanoma Research. 2017;27(2):155-158. https://doi.org/10.1097/CMR.0000000000000314
Levina VD, Poltavskaya MG, Chomakhidze PSh, et al. High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity. Rossijskij kardiologicheskij zhurnal. 2022; 27(11):5210. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5210
Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for detecting anthracycline cardiotoxicity in adults with hematological malignancies. Annals of Hematology. 2003;82:218-222. https://doi.org/10.1007/s00277-003-0615-3
Verett BM. Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. Trends in Cardiovascular Medicine. 2017; 27:41-47. https://doi.org/10.1016/j.tcm.2016.06.002
Chaulin AM, Duplyakov DV. Increased natriuretic peptides not associated with heart failure. Rossijskij kardiologicheskij zhurnal. 2020;25(4S):4140. (In Russ.). https://doi.org/10.15829/1560-4071-2020-4140
Bagge NVJ, van den Bosch AE, Eindhoven JA, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide, troponin-T and growth differentiation factor-15 in congenital heart defects in adults. Circulation. 2017; 135:264-279. https://doi.org/10.1161/CIRCULATIONAHA.116.023255
Brown C, Mantzaris M, Nicolaou E, et al. Systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients: potential panels and research challenges. Cardio-Oncology. 2022;8:16. https://doi.org/10.1186/s40959-022-00142-1
Zhou Y, Jia WK, Jian Z, et al. Downregulation of microRNA-199a-5p protects cardiomyocytes in cyanotic congenital heart disease by attenuating endoplasmic reticulum stress. Molecular Medicine Reports. 2017;16(3):2992-3000. https://doi.org/10.3892/mmr.2017.6934
Meng X, Mei L, Zhao C, et al. miR-885 mediated cardioprotection against hypoxia/reoxygenation-induced apoptosis in human cardiomyocytes via inhibition of PTEN and BCL2L11 and modulation of AKT/mTOR signaling. Journal of Cellular Physiology. 2020;235(10):8048-8057. https://doi.org/10.1002/jcp.29460
Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncology. 2018;4(11):1553-1568. https://doi.org/10.1001/jamaoncol.2018.2706
Pudil R. The future role of cardio-oncologists. Cardiac Failure Review. 2017;3(2):1402. https://doi.org/10.15420/cfr.2017:16:1
Vasyuk YA, Shupenina EY, Vyzhigin DA, et al. Kardioonkologiya. Rukovodstvo dlya vrachej. M.: GEOTAR-Media. 2025. (In Russ.).
Zhukov NV, Rumyantsev AG. Development of oncology. From despair to hope... Oncohematology. 2013;8(3):6-15. (In Russ.).
Buziashvili YI, Asymbekova EU, Tugeeva EF, et al. The role of artificial intelligence in cardio-oncology: present and future. Consilium Medicum. 2023; 25(1):29-33. (In Russ.). https://doi.org/10.26442/20751753.2023.1.202095
Madan N, Lucas J, Akhter N, et al. Artificial intelligence and imaging: opportunities in cardio-oncology. American Heart Journal Plus. 2022;15:100126. https://doi.org/10.1016/j.ahjo.2022.100126
Dey D, Slomka P, Leeson P, et al. Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. Journal of the American College of Cardiology. 2019;73(11):1317-1335. https://doi.org/10.1016/j.jacc.2018.12.054
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with EHA, ESTRO, and IC-OS: developed by the ESC Cardio-Oncology Task Force. European Heart Journal. 2022;43(41):4229-4361. https://doi.org/10.1093/eurheartj/ehac244
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Sarker I. Machine learning: algorithms, real-world applications and research directions. SN Computer Science. 2021;2(3):160. https://doi.org/10.1007/s42979-021-00592-x
Martinez D, Noseworthy P, Akbilgic O, et al. Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography. American Heart Journal Plus. 2022;15:100129.